Los Angeles, California (PRWEB) October 17, 2014

Anticonvulsant drugs have a buyer power score of 2.1 out of 5. The score reflects this market’s negative pricing trends and indicates a low level of buyer negotiating power. During the three years to 2014, prices of anticonvulsants have been trending continuously upward due to increasing demand for epilepsy treatment and rising production costs. IBISWorld market research analyst, Anna Son, says, “As the economy has slowly been recovering and people have been gaining health coverage, demand for anticonvulsants has been increasing.” The broadening use of anticonvulsants to treat other conditions has further bolstered demand. Despite the abundance of anticonvulsants on the market, manufacturers will continue expanding their research and development (R&D) efforts to commercialize new medications due to an unmet need for more effective drugs. As a result, suppliers will likely adjust their drug prices upward to recoup heightened production costs.

The anticonvulsants market is highly concentrated at the manufacturing level, with large-cap pharmaceutical firms like Pfizer, UCB and Abbott Laboratories dominating the market. “In light of patent expirations on their blockbuster drugs, these pharmaceutical giants have been actively acquiring other marketplace players to reinforce their dwindling product pipelines,” says Son. This consolidation activity is expected to continue in the next three years and can diminish buyer power as top suppliers gain greater market shares. In contrast, rising pricing competition from generic anticonvulsants and pressure for cost containment will help buyers maintain their bargaining power in the coming years.

Based on the nature of their operations, buyers such as healthcare providers may have a difficult time switching suppliers due to potential risks to patient health and safety. While switching to less expensive generics may be cost effective, buyers should be aware that a generic anticonvulsant may not provide the same results as its brand name equivalent. The difficulty of switching from one type of anticonvulsant to another produced by another manufacturer restrains buyer power, leaving less room for price negotiation. For more information, visit IBISWorld’s Anticonvulsants procurement category market research report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Like IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld Procurement Report Key Topics

This report is intended to assist buyers of anticonvulsants, which represent a diverse group of medicines used in the treatment of epileptic seizures. Anticonvulsants are also used as a treatment for neuropathic pain and in the treatment of bipolar disorder because they act as mood stabilizers and. Anticonvulsants are also known as antiepileptic drugs and are sometimes referred to as antiseizure drugs.

Executive Summary

Pricing Environment

Price Fundamentals

Benchmark Price

Pricing Model

Price Drivers

Recent Price Trend

Price Forecast

Product Characteristics

Product Life Cycle

Total Cost of Ownership

Product Specialization

Substitute Goods

Regulation

Quality Control

Supply Chain & Vendors

Supply Chain Dynamics

Supply Chain Risk

Imports

Competitive Environment

Market Share Concentration

Market Profitability

Switching Costs

Purchasing Process

Buying Basics

Buying Lead Time

Selection Process

Key RFP Elements

Negotiation Questions

Buyer Power Factors

Key Statistics

About IBISWorld Inc.

IBISWorld is one of the world’s leading publishers of business intelligence, specializing in Industry research and Procurement research. Since 1971, IBISWorld has provided thoroughly researched, accurate and current business information. With an extensive online portfolio, valued for its depth and scope, IBISWorld’s procurement research reports equip clients with the insight necessary to make better purchasing decisions, faster. Headquartered in Los Angeles, IBISWorld Procurement serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.






More Medicine Press Releases